ColoAlert can identify more colorectal cancer cases than other stool tests. Credit: crystal light / Shutterstock.com.

Mainz Biomed has announced a strategic collaboration with Bioclinica to support the commercialisation of its ColoAlert test in Romania.

ColoAlert is a user-friendly at-home detection test for colorectal cancer (CRC).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

By analysing tumour DNA, this non-invasive test provides better early detection of tumours compared to faecal occult blood tests.

The test, which is based on polymerase chain reaction technology, enables an earlier diagnosis and can identify more colorectal cancer cases than other stool tests.

ColoAlert is expected to benefit more than six million people aged between 50 and 74 years in Romania, a country with one of the highest CRC incidence rates in Europe.

Mainz Biomed chief commercial officer Darin Leigh said: “In executing our commercial strategy, we remain steadfast in aligning ourselves with laboratories that share our unwavering dedication to introducing cutting-edge diagnostic tests capable of making a profound impact on the treatment and prevention of critical diseases like CRC.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Early detection is paramount in enhancing patient survival rates and our partnership with Bioclinica in Romania exemplifies our commitment to this cause.”

The company is already marketing ColoAlert in select European Union countries via direct sales, corporate health programmes and independent laboratories network.

It is also being assessed in the US Food and Drug Administration registration study, ReconAAsense, which will help secure marketing approval in the country.

Bioclinica offers modern diagnostics to people in Romania through its 15 associated laboratories and 146 collection points.